Skip to main content
SpringerLink
Log in

Differential Effect of Taxol in Rat Primary and Metastatic Prostate Tumors: Site-Dependent Pharmacodynamics

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. This study compared the sensitivity of rat prostate MAT-LyLu primary and lymph node metastatic tumors to taxol.

Methods. Tumors were established by subcutaneous implantation of tumor cells in a hind leg (primary site) of male Copenhagen rats. Lymph node metastases were used for serial transplantation. Eleven pairs of primary and metastatic tumors between the sixth and twentieth generations were harvested and maintained as 3-dimensional histocultures. The effects of taxol (24 hr treatment at 1 nM to 10 µM) were measured by the appearance of apoptotic cells, and by the inhibition of DNA precursor (thymidine) incorporation. To determine the basis of differential sensitivity of primary and metastatic tumors to the DNA inhibition, we examined the expression of multidrug resistance p-glycoprotein (Pgp) and the accumulation of 3H-taxol after 24 hr exposure and the retention after a 48 hr washout period.

Results. The fraction of apoptotic cells increased linearly with the logarithm of taxol concentration to a maximal value of 25%; the concentration-response curves for primary and metastatic tumors were superimposable. Taxol produced a sigmoidal, concentration-dependent inhibition of thymidine incorporation; the maximal inhibition of ~40% was reached at 0.1 and 1 µM for primary and metastatic tumors, respectively. Within the primary or metastatic subgroups, the IC30 (drug concentration that produced a 30% inhibition of DNA synthesis) among consecutive generations varied by < 5 fold, but the primary tumor consistently showed a lower IC30 than the daughter or the parent metastatic tumor (mean, 20-fold; median, 15-fold; range, 6- to 56-fold). The finding that the lower drug sensitivity in metastatic tumors was not exhibited in its daughter primary tumor but was regained in its daughter metastatic tumors suggests that the chemoresistant phenotype is maintained only in lymph nodes and not in the primary site. There were no differences in the Pgp status (neither tumor expressed Pgp), accumulation and retention of taxol in primary and metastatic tumors.

Conclusions. Taxol induced apoptosis and inhibited DNA synthesis in the rat MAT-LyLu primary and lymph node metastatic tumors. The apoptotic effect was not different among the two tumors, whereas the primary tumor was more sensitive to the inhibition of DNA synthesis. The differential sensitivity of the two tumors to the DNA effect is not associated with a difference in Pgp expression, drug accumulation nor drug retention, and appears to be associated with changes that are linked to lymph node metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. E. K. Rowinsky, N. Onetto, R. M. Canetta, and S. G. Arbuck. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin. Oncol. 19:646–662 (1992).

    Google Scholar 

  2. S. G. Arbuck and B. Blaylock. Taxol: Clinical results and current issues in development. In Suffness, M. (ed), Taxol-Science and Applications, Boca Raton, 1995, pp. 379–415.

  3. S. B. Horwitz. Taxol (paclitaxel): Mechanism of action. Annuals Oncol. 5:53–56 (1994).

    Google Scholar 

  4. K. L. Crossin and D. H. Carney. Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and epidermal growth factor. Cell 27:341–350 (1981).

    Google Scholar 

  5. Y. Liu, K. Bhalla, C. Hill, and D. G. Priest. Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem. Pharmacol. 48:1265–1272 (1994).

    Google Scholar 

  6. K. Bhalla, A. M. Ilerado, E. Tourkina, C. Tang, M. E. Mahoney, and Y. Huang. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7:563–568 (1993).

    Google Scholar 

  7. L. Milas, N. R. Hunter, and B. Kurdoglu. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother. Pharmacol. 35:297–303 (1995).

    Google Scholar 

  8. M. E. Stearns and M. Wang. Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastasis. Cancer Res. 52:3776–3781 (1992).

    Google Scholar 

  9. S. B. Horwitz, D. Cohen, S. Rao, I. Ringel, H. J. Shen and C. P. H. Yang. Taxol: Mechanisms of action and resistance. J. Natl. Cancer Inst. 15:55–61 (1993).

    Google Scholar 

  10. S. Roy and S. B. Horwitz. A phosphoglycoprotein associated with taxol-resistance in J774.2 cells. Cancer Res. 45:3856–3863 (1985).

    Google Scholar 

  11. K. Bhalla, Y. Huang, C. Tang, S. Self, S. Ray, M. E. Mahoney, V. Ponnathpur, E. Tourkina, A. M. Ibrado, and G. Bullock. Characterization of a human myeloid cell line highly resistant to taxol. Leukemia 8:465–475 (1994).

    Google Scholar 

  12. L. A. Speicher, L. R. Barone, A. E. Chapman, G. R. Hudes, N. Laning, C. D. Smith, and K. D. Tew. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J. Natl. Cancer Inst. 86:688–694 (1994).

    Google Scholar 

  13. G. H. Mickisch, T. Licht, G. T. Merlino, M. M. Gottesman, and I. Pastan. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Cancer Res. 51:5417–5424 (1991).

    Google Scholar 

  14. B. Jachez, R. Nordmann, and F. Loor. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280–446. J. Natl. Cancer Inst. 85:478–483 (1993).

    Google Scholar 

  15. M. Lenert, S. Emerson, S. D. William, R. de Giuli, and S. E. Salmon. In vitro evaluation of chemosensitizers for clinical reversal of p-glycoprotein-associated taxol resistance. Monogr. Natl. Cancer Inst. 15:63–67 (1993).

    Google Scholar 

  16. J. R. Roberts, D. C. Allison, R. C. Sonehower, E. K. Rowinsky. Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Res. 50:710–716 (1990).

    Google Scholar 

  17. J. E. Liebmann, S. M. Hahn, J. A. Cook, C. Lipschultz, J. B. Mitchell, and D. C. Kaufman. Glutathione depletion of L-buthionine sulfoximine antagonizes taxol cytotoxicity. Cancer Res. 53:2066–2070 (1993).

    Google Scholar 

  18. F. C. Lowe, and J. T. Isaacs. Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the Dunning R-3327 rat prostatic adenocarcinoma system as a model. Cancer Res. 44:744–752 (1984).

    Google Scholar 

  19. R. A. Vesico, C. H. Redfern, T. J. Nelson, S. Ugoretz, P. H. Stern, and R. M. Hoffman. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc. Natl. Acad. Sci. U.S.A. 84:5029–5033 (1987).

    Google Scholar 

  20. F. H. Schroeder and S. J. Mackensen. Human prostatic adenoma and carcinoma in cell culture-effects of androgen-free culture medium. Invest. Urol. 12:176–181 (1974).

    Google Scholar 

  21. D. D. Mickey. Growth and differentiation factors in prostatic tissue. In M. Motta and M. Serio (eds), Hormonal therapy of prostatic diseases: basic and clinical aspects, Medicom, Bussum, The Netherlands, 1988, pp 13–47.

    Google Scholar 

  22. M. G. Wientjes, T. G. Pretlow, R. A. Badalament, J. K. Burgers, and J. L.-S. Au. Histocultures of human prostate tissues for pharmacologic evaluation. J. Urol. 153:1299–1302 (1995).

    Google Scholar 

  23. D. R. Kohler, and B. R. Goldspiel. Paclitaxel (taxol). Pharmacotherapy 14:3–34 (1994).

    Google Scholar 

  24. J. F. R. Kerr, M. Clay, and B. V. Harmon. Apoptosis: Its significance in cancer and cancer therapy. Cancer 73:2013–2026 (1994).

    Google Scholar 

  25. Y. Gan, M. G. Wientjes, D. E. Schuller, and J. L.-S. Au. Pharmacodynamics of taxol in human head and neck tumors. Cancer Res. 56:2086–2093 (1996).

    Google Scholar 

  26. N. M. Lopes, E. G. Adams, T. W. Pitts, B. K. Bhuyan. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol. 32:235–242 (1993).

    Google Scholar 

  27. J. Liebmann, J. A. Cook, C. Lipschultz, D. Teague, J. Fisher, and J. B. Mitchell. The influence of Cremophor EL on the cell cycle effects of paclitaxel (taxol) in human tumor cell lines. Cancer Chemother. Pharmacol. 33:331–339 (1994).

    Google Scholar 

  28. J. L.-S. Au, N. E. Millenbaugh, J. E. Kalns, C. T. Chen, and M. G. Wientjes. Pharmacodynamics of taxol in human solid tumors. Proc. Am. Assoc. Cancer Res. 35:426 (1994).

    Google Scholar 

  29. J. L.-S. Au, M. G. Wientjes, T. J. Rosol, A. Koolemans-Beynen, E. A. Goebel, and D. E. Schuller. Histocultures of patient head and neck tumors for pharmacodynamic studies. Pharm. Res. 10:1493–1499 (1993).

    Google Scholar 

  30. T. S. Schmittgen, M. G. Wientjes, R. A. Badalament, and J. L.-S. Au. Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res. 51:3849–3856 (1991).

    Google Scholar 

  31. Y. Gan, M. G. Wientjes, R. A. Badalament, and J. L.-S. Au. Pharmacodymamics of doxorubicin in human bladder tumors. Clin. Cancer Res. In press (1996).

  32. T. Cresteil, B. Monsarrat, P. Alvinerie, J. M. Treluyer, I. Vieira, and M. Wright. Taxol metabolism by human liver microsomes: identification of cytochrome p450 isozymes involved in its transformation. Cancer Res. 54:386–392 (1994).

    Google Scholar 

  33. I. Kjonniksen, B. Knut, and O. Fodstad. Site-dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide but not to doxorubicin and cisplatin. Cancer Res. 52:1347–1351 (1992).

    Google Scholar 

  34. C. Wilmanns, D. Fan, C. A. O'Brian, C. D. Bucana, and I. J. Fidler. Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. In. J. Cancer. 52:98–104 (1992).

    Google Scholar 

  35. C. Wilmanns, D. Fan, C. A. O'Brian, R. Radinsky, C. D. Bucana, R. Tsan and I. J. Fidler. Modulation of doxorubicin sensitivity and level of P-glycoprotein expression in human colon carcinoma cells by ectopic and orthotopic environments in nude mice. Int. Oncol. 3:413–422 (1993).

    Google Scholar 

  36. T. Furukawa, T. Kubota, M. Watanabe, T.-H. Kuo, M. Kitajima, and R. M. Hoffman. Differential chemosensitivity of local and metastatic human gastric cancer after orthotopic transplantation of histologically intact tumor tissue in nude mice. Int. J. Cancer. 54:397–401 (1993).

    Google Scholar 

  37. I. J. Fidler, C. Wilmanns, A. Staroselsky, R. Radinsky, Z. Dong, and D. Fan. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metast. Rev. 13:209–222 (1994).

    Google Scholar 

  38. B. A. Teicher, T. S. Herman, S. A. Holden, Y. Wang, M. R. Pfeffer, J. W. Crawford, and E. Frei. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247:1457–1461 (1990).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, Ohio State University, Columbus, Ohio

    Wan-Ching Yen, M. Guillaume Wientjes & Jessie L.-S. Au

  2. Division of Urology, College of Medicine, Ohio State University, Columbus, Ohio

    M. Guillaume Wientjes & Jessie L.-S. Au

  3. Comprehensive Cancer Center, Ohio State University, Columbus, Ohio

    M. Guillaume Wientjes & Jessie L.-S. Au

Authors
  1. Wan-Ching Yen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Guillaume Wientjes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jessie L.-S. Au
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yen, WC., Wientjes, M.G. & Au, J.LS. Differential Effect of Taxol in Rat Primary and Metastatic Prostate Tumors: Site-Dependent Pharmacodynamics. Pharm Res 13, 1305–1312 (1996). https://doi.org/10.1023/A:1016053412582

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016053412582

Search

Navigation